L-Carnitine Injectable

Oral L-Carnitine bioavailability is approximately 15-20% — the majority is degraded by intestinal bacteria and first-pass liver metabolism. Injectable L-Carnitine bypasses GI absorption entirely, achieving 4-6x higher plasma and tissue concentrations from the same dose. For therapeutic repletion or acute performance enhancement, injectable administration delivers the compound where it needs to be.

L-Carnitine facilitates fat oxidation but does not independently cause fat loss without an appropriate caloric environment and physical activity. It is best understood as a fat oxidation enabler that maximises the efficiency of fat burning during caloric deficit and exercise rather than a standalone weight loss agent.

Research shows that daily oral supplementation for 4 weeks significantly increases skeletal muscle carnitine content. With injectable administration the saturation timeline is compressed. Once saturated, maintenance dosing (less frequent) is sufficient to sustain elevated tissue concentrations.

Acetyl-L-Carnitine (ALCAR) crosses the blood-brain barrier and has nootropic properties, including acetylcholine precursor activity and neuroprotective effects. L-Carnitine is the peripheral form with superior fat oxidation and exercise performance effects. They are used for different purposes, though some overlap in general metabolic support.

L-Carnitine has one of the longest and most well-established safety records of any nutritional compound. Decades of clinical data in dialysis patients, heart failure patients, and athletes show no significant adverse effects at doses up to 3000 mg daily. It is classified as Generally Recognised As Safe by the FDA.

For fat oxidation purposes, administering L-Carnitine in a fasted or low-insulin state and timing it before aerobic exercise produces the greatest effect on fat substrate utilisation. The combination of fasted state + carnitine + aerobic exercise maximises free fatty acid mobilisation and mitochondrial uptake.